These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 22407972)

  • 21. A Bayesian design and analysis for dose-response using informative prior information.
    Smith MK; Marshall S
    J Biopharm Stat; 2006; 16(5):695-709. PubMed ID: 17037266
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combining multiple comparisons and modeling techniques in dose-response studies.
    Bretz F; Pinheiro JC; Branson M
    Biometrics; 2005 Sep; 61(3):738-48. PubMed ID: 16135025
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improved up-and-down designs for phase I trials.
    Ivanova A; Montazer-Haghighi A; Mohanty SG; Durham SD
    Stat Med; 2003 Jan; 22(1):69-82. PubMed ID: 12486752
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimal designs for estimating the most successful dose.
    Zohar S; O'Quigley J
    Stat Med; 2006 Dec; 25(24):4311-20. PubMed ID: 16969893
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Estimating dose equivalence for new routes of drug administration.
    Weerakkody G; Gonzales C; Muchmore D; Chien J
    J Biopharm Stat; 2004 Nov; 14(4):1021-36. PubMed ID: 15587978
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Determining causal exposure-response relationships with randomized concentration-controlled trials.
    Wang J
    J Biopharm Stat; 2014; 24(4):874-92. PubMed ID: 24697561
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The influence of underlying assumptions on evaluating the relative merits of concentration-controlled and dose-controlled trials.
    Lledó-García R; Hennig S; Karlsson MO
    Clin Pharmacol Ther; 2009 Jul; 86(1):70-6. PubMed ID: 19279565
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An autoregressive linear mixed effects model for the analysis of unequally spaced longitudinal data with dose-modification.
    Funatogawa I; Funatogawa T
    Stat Med; 2012 Mar; 31(6):589-99. PubMed ID: 22170221
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The minimum anticipated biological effect level (MABEL) for selection of first human dose in clinical trials with monoclonal antibodies.
    Muller PY; Milton M; Lloyd P; Sims J; Brennan FR
    Curr Opin Biotechnol; 2009 Dec; 20(6):722-9. PubMed ID: 19896825
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The need for modeling and simulation to design clinical investigations in children.
    Jadhav PR; Kern SE
    J Clin Pharmacol; 2010 Sep; 50(9 Suppl):121S-129S. PubMed ID: 20881225
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose.
    Contrera JF; Matthews EJ; Kruhlak NL; Benz RD
    Regul Toxicol Pharmacol; 2004 Dec; 40(3):185-206. PubMed ID: 15546675
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identifying potential adverse events dose-response relationships via Bayesian indirect and mixed treatment comparison models.
    Fu H; Price KL; Nilsson ME; Ruberg SJ
    J Biopharm Stat; 2013; 23(1):26-42. PubMed ID: 23331219
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bayesian adjustment for covariate measurement errors: a flexible parametric approach.
    Hossain S; Gustafson P
    Stat Med; 2009 May; 28(11):1580-600. PubMed ID: 19226564
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dose finding - a challenge in statistics.
    Bretz F; Hsu J; Pinheiro J; Liu Y
    Biom J; 2008 Aug; 50(4):480-504. PubMed ID: 18663758
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A linearization approach for the model-based analysis of combined aggregate and individual patient data.
    Ravva P; Karlsson MO; French JL
    Stat Med; 2014 Apr; 33(9):1460-76. PubMed ID: 24488864
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dose as instrumental variable in exposure-safety analysis using count models.
    Wang J
    J Biopharm Stat; 2012; 22(3):565-81. PubMed ID: 22416841
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Non-parametric estimators of a monotonic dose-response curve and bootstrap confidence intervals.
    Dilleen M; Heimann G; Hirsch I
    Stat Med; 2003 Mar; 22(6):869-82. PubMed ID: 12627406
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The utility of mixed-effects covariate analysis in rapid selection of doses in pediatric subjects: a case study with fexofenadine hydrochloride.
    Krishna R; Krishnaswami S; Kittner B; Sankoh AJ; Jensen BK
    Biopharm Drug Dispos; 2004 Dec; 25(9):373-87. PubMed ID: 15517550
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Escalation, group and A + B designs for dose-finding trials.
    Ivanova A
    Stat Med; 2006 Nov; 25(21):3668-78. PubMed ID: 16381057
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Designs for dose-escalation trials with quantitative responses.
    Bailey RA
    Stat Med; 2009 Dec; 28(30):3721-38. PubMed ID: 19579226
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.